• |
  • |
  • |
  • |
Donate

Product

Journal: Controlled Trial of Metformin in Fragile X Syndrome

Center:
Fiscal Year:
2026
Contact Information:
Product Description:
This RCT of metformin in children (6 and older) and adults with FXS generally demonstrated improvement in behaviour; this is consistent with clinical observations in FXS. It supports that metformin is a targeted treatment for FXS behaviour symptoms and can be recommended clinically.
Keyword(s):
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals
Alternative Format:
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A